These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24355920)

  • 1. Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir.
    Coriat R; Alexandre J; Nicco C; Quinquis L; Benoit E; Chéreau C; Lemaréchal H; Mir O; Borderie D; Tréluyer JM; Weill B; Coste J; Goldwasser F; Batteux F
    J Clin Invest; 2014 Jan; 124(1):262-72. PubMed ID: 24355920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The search for treatments to reduce chemotherapy-induced peripheral neuropathy.
    Pachman DR; Loprinzi CL; Grothey A; Ta LE
    J Clin Invest; 2014 Jan; 124(1):72-4. PubMed ID: 24355918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca
    Karlsson JOG; Jynge P
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx
    Glimelius B; Manojlovic N; Pfeiffer P; Mosidze B; Kurteva G; Karlberg M; Mahalingam D; Buhl Jensen P; Kowalski J; Bengtson M; Nittve M; Näsström J
    Acta Oncol; 2018 Mar; 57(3):393-402. PubMed ID: 29140155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.
    Alexandre J; Nicco C; Chéreau C; Laurent A; Weill B; Goldwasser F; Batteux F
    J Natl Cancer Inst; 2006 Feb; 98(4):236-44. PubMed ID: 16478742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
    Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
    Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
    Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.
    Padman S; Lee J; Kumar R; Slee M; Hakendorf P; Richards A; Koczwara B; Kichenadasse G; Sukumaran S; Roy A; Vatandoust S; Karapetis CS
    Support Care Cancer; 2015 Mar; 23(3):861-9. PubMed ID: 25223350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Promising effects of pregabalin in the treatment of oxaliplatin-induced sensory neuropathy in patients with colorectal carcinoma].
    Nagahara H; Noda E; Maeda K; Inoue T; Hirakawa T; Hasegawa T; Shibutani M; Hirakawa K
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1181-3. PubMed ID: 24047775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
    Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
    Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
    Vatandoust S; Joshi R; Pittman KB; Esterman A; Broadbridge V; Adams J; Singhal N; Yeend S; Price TJ
    Support Care Cancer; 2014 Feb; 22(2):513-8. PubMed ID: 24122404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
    Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
    Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
    Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
    Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of oxaliplatin-induced neuropathy: a patient perspective.
    Bennett BK; Park SB; Lin CS; Friedlander ML; Kiernan MC; Goldstein D
    Support Care Cancer; 2012 Nov; 20(11):2959-67. PubMed ID: 22426503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
    Shahriari-Ahmadi A; Fahimi A; Payandeh M; Sadeghi M
    Asian Pac J Cancer Prev; 2015; 16(17):7603-6. PubMed ID: 26625769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice.
    Qin Y; Iwase A; Murase T; Bayasula ; Ishida C; Kato N; Nakamura T; Osuka S; Takikawa S; Goto M; Kotani T; Kikkawa F
    Reprod Biol Endocrinol; 2018 Oct; 16(1):106. PubMed ID: 30368246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
    Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.
    Gent P; Massey K
    Int J Palliat Nurs; 2001 Jul; 7(7):354-9. PubMed ID: 11951404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.